In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regenxbio Inc.

https://regenxbio.com/

Latest From Regenxbio Inc.

After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy

CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.

Companies Clinical Trials

Two Very Different Flavors Of Ocular Gene Therapy Get A Boost

The 2021 collaboration between Abbvie and Regenxbio to develop an anti-VEGF gene therapy for chronic retinal diseases is a noteworthy deal in the gene therapy space. But for both clinical and commercial reasons, it is a one-off opportunity and not an indicator of the overall potential of gene therapies to address eye diseases. Interest in optogenetics, however, which is the introduction of light-sensing genes into cells in the eye to restore vison, may be on the rise.

Gene Therapy Deals

AAV Vector Consortia Address Quality Assays, Endpoints

Two outside groups aim to help CBER on gene therapy questions from ‘N of one’ to markers for hemophilia.

Gene Therapy Drug Approval Standards

With Vuity Approval, AbbVie Continues Stepping Into Eye Care

AbbVie had no presence in ophthalmic medicine other than a single indication for Humira before the Allergan merger, but now has a growing eye care portfolio, including early FDA approval of Vuity for presbyopia.

Approvals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • ReGenX, LLC
    • ReGenX Biosciences, LLC
UsernamePublicRestriction

Register